ArticleInternational journal of clinical and experimental pathology2012
Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Article in International journal of clinical and experimental pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Comparing the Expression of Estrogen Receptors, Progesterone Receptors, and Human Epidermal Growth Factor Receptor 2 Between Initial Biopsy and Excision Specimens in Invasive Breast Carcinoma Cases. Is There a Need for Universal Repeat Testing? Experience From a Community Hospital.HCA healthcare journal of medicine · 2026Article
- Changes in HER2, ER, PR, and Ki-67 in HER2-Negative Breast Cancer After Neoadjuvant Chemotherapy: A Case-Control Study.Current oncology (Toronto, Ont.) · 2025Article
- Molecular shifts in breast cancer following neoadjuvant chemotherapy: a prospective study and review of literature.Future oncology (London, England) · 2025Review
- Differentiating Primary and Recurrent Lesions in Patients with a History of Breast Cancer: A Comprehensive Review.Galen medical journal · 2024Article
- Immunohistochemical and Clinicopathological Characteristics of Invasive Breast Carcinoma in Nigeria.Oman medical journal · 2023Article
- Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy.Breast cancer research and treatment · 2023Article
- The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer.Frontiers in oncology · 2021Article
- Effect of neoadjuvant therapy on breast cancer biomarker profile.BMC cancer · 2020Article
- Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer.Experimental and therapeutic medicine · 2019Article
- Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer.International journal of molecular medicine · 2019Article
- The correlation between mammographic densities and molecular pathology in breast cancer.Cancer biomarkers : section A of Disease markers · 2018Article
- Article
- Invasive Ductal Carcinoma Breast: How Neoadjuvant Chemotherapy Affects the Status of Estrogen Receptor, Progesterone Receptor and HER2/Neu-A Tertiary Care Centre Study.Journal of clinical and diagnostic research : JCDR · 2017Article
- Effect of neoadjuvant chemotherapy on HER-2 expression in surgically treated gastric and oesophagogastric junction carcinoma: a multicentre Italian study.Updates in surgery · 2017Article
- Association of T-cadherin levels with the response to neoadjuvant chemotherapy in locally advanced breast cancer.Oncotarget · 2017Article
- Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.Journal of gastrointestinal oncology · 2016Article
- Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma.World journal of surgical oncology · 2015Article
- Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?Breast cancer (Dove Medical Press) · 2015Article
- Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer.Molecular and clinical oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe estrogen receptor (ER), progesterone receptor (PR), and HER2 profile of a primary breast carcinoma plays a significant role in patient management and treatment. Because of the increasing utilization of neoadjuvant chemotherapy or hormone therapy, surgically-resected carcinomas often show marked treatment effect. The aim of this study was to compare immunohistochemical (IHC) profiles (ER, PR, HER2, HER2 FISH) of primary breast carcinomas before and after neoadjuvant chemotherapy to assess the subsequent effects on hormone receptor status.
designPrimary breast carcinomas from 38 female patients treated with neoadjuvant therapy after needle core biopsy or fine needle aspiration diagnosis were included. Histologic data was collected for each case, including site, type, grade, tumor size (cm), pre- and post- neoadjuvant treatment IHC panel (ER, PR, HER2), and fluorescence in-situ hybridization (FISH) for HER2.
resultsOf the 38 carcinomas studied, 45 % were positive for ER by IHC both pre- and post- neoadjuvant treatment (P=1.00). IHC studies for PR in these 38 patients showed 37% positivity for PR pre-neoadjuvant therapy and 21% positivity post-treatment (p=0.03). For 37 patients with HER2 IHC, 32% were positive pre-treatment, and 22% were positive post-treatment (P = 0.20). For 7 patients, HER2 FISH was positive in 71% pre-therapy and in 57% post-treatment (P=0.32).
conclusionsProfiles for ER, HER2 IHC, and HER2 FISH were not significantly different in primary breast carcinomas before and after neoadjuvant chemotherapy. Further investigation is warranted to assess reproducibility of technique and investigate clinical implications of significant loss of PR status in treated patients.
Indexed as
Identifiers
22949935PMC3430104W1560977309What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.